Pfizer Appeals £63M CMA Epilepsy Drug Pricing Fine
Pfizer said Monday that the price for its anti-epilepsy tablets was benchmarked to a fair rate set by the government, at the start of a challenge to a £63.3 million ($78.3...To view the full article, register now.
Already a subscriber? Click here to view full article